{Reference Type}: Journal Article
{Title}: Effect of inferior caval valve implantation on circulating immune cells and inflammatory mediators in severe tricuspid regurgitation.
{Author}: Mattig I;Hewing B;Knebel F;Meisel C;Ludwig A;Konietschke F;Stangl V;Stangl K;Laule M;Dreger H;
{Journal}: BMC Cardiovasc Disord
{Volume}: 24
{Issue}: 1
{Year}: 2024 Jul 18
{Factor}: 2.174
{DOI}: 10.1186/s12872-024-04044-1
{Abstract}: <B>BACKGROUND: </B>Interventional valve implantation into the inferior vena cava (CAVI) lowers venous congestion in patients with tricuspid regurgitation (TR). We evaluated the impact of a reduction of abdominal venous congestion following CAVI on circulating immune cells and inflammatory mediators.<BR><B>METHODS: </B>Patients with severe TR were randomized to optimal medical therapy (OMT) + CAVI (n = 8) or OMT (n = 10). In the OMT + CAVI group, an Edwards Sapien XT valve was implanted into the inferior vena cava. Immune cells and inflammatory mediators were measured in the peripheral blood at baseline and three-month follow-up.<BR><B>RESULTS: </B>Leukocytes, monocytes, basophils, eosinophils, neutrophils, lymphocytes, B, T and natural killer cells and inflammatory markers (C-reactive protein, interferon-gamma, interleukin-2, -4, -5, -10, and tumor necrosis factor-alpha) did not change substantially between baseline and three-month follow-up within the OMT + CAVI and OMT group.<BR><B>CONCLUSIONS: </B>The present data suggest that reduction of venous congestion following OMT + CAVI may not lead to substantial changes in systemic inflammation within a short-term follow-up.<BR><B>BACKGROUND: </B>NCT02387697.